<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01676233</url>
  </required_header>
  <id_info>
    <org_study_id>PDY12335</org_study_id>
    <secondary_id>U1111-1129-3633</secondary_id>
    <nct_id>NCT01676233</nct_id>
  </id_info>
  <brief_title>Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Open-label, 2-treatment Crossover Study of a New Formulation of Insulin Glargine Comparing to Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus on Treatment With Basal-bolus Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      - To compare the 24-hour glycemic profile in continuous glucose monitoring (CGM) between a
      new formulation of insulin glargine and Lantus at steady state

      Secondary Objectives:

        -  To compare the change of Fasting plasma glucose (FPG), Self-monitoring plasma glucose
           (SMPG) and Postprandial Plasma Glucose (PPG) between the 2 treatments;

        -  To compare the efficacy of the 2 treatments on glycemic control in glycemic parameters
           (1,5-anhydroglucitol and hemoglobin A1c (glycosylated hemoglobin; HbA1c));

        -  To compare the occurrence of hypoglycemia between the 2 treatments;

        -  To assess the safety and tolerability of a new formulation of insulin glargine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      66 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-hour blood glucose profile measured by continuous glucose monitoring</measure>
    <time_frame>Baseline, Day 28, Day 56</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia categorized by the definition of American Diabetes Association</measure>
    <time_frame>Up to Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose from baseline to each treatment end by treatment</measure>
    <time_frame>Baseline, Day 28, Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self monitoring plasma glucose profile from baseline to each treatment end by treatment</measure>
    <time_frame>Baseline, Day 28, Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from baseline to each treatment end by treatment</measure>
    <time_frame>Baseline, Day 28, Day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference (insulin glargine) -Test1 (insulin glargine - new formulation), both dose will be adjusted individually to achieve the target glycemic goal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test1 - Reference , both dose will be adjusted individually to achieve the target glycemic goal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine (HOE901)</intervention_name>
    <description>Pharmaceutical form: solution Route of administration: subcutaneous</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine- new formulation (HOE901)</intervention_name>
    <description>Pharmaceutical form: solution Route of administration: subcutaneous</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Japanese patients with Type 1 Diabetes Mellitus (T1DM) on treatment with basal-bolus
             insulin;

        Exclusion criteria:

          -  Age &lt; 20 years at written informed consent;

          -  HbA1c &lt; 6.5% or &gt; 10.0% at screening

          -  Diabetes mellitus (DM) other than T1DM;

          -  Body Mass Index (BMI) &gt; 35.0 kg/m2 at screening visit

          -  Any contraindication to use of insulin glargine as defined in the Japanese Package
             Insert

          -  Hypoglycemia unawareness or history of metabolic acidosis, including hospitalization
             for diabetic ketoacidosis during the 24 weeks prior to screening visit

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Kumamoto-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2012</study_first_submitted>
  <study_first_submitted_qc>August 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2012</study_first_posted>
  <last_update_submitted>August 16, 2013</last_update_submitted>
  <last_update_submitted_qc>August 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

